Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
780 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00142168 | CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia | terminated | Phase 2 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 21, 2016 | clinicaltrials |
| NCT00903162 | Extended Endocrine Therapy for Premenopausal Women With Breast Cancer | completed | Phase 2 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 18, 2016 | clinicaltrials |
| NCT00250926 |
| Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia |
| completed |
| Phase 2 |
| 23 |
| Dana-Farber Cancer InstituteOTHER |
| 1 |
| Apr 8, 2016 |
| clinicaltrials |
| NCT01249105 | MK-2206 for Recurrent Malignant Glioma | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2016 | clinicaltrials |
| NCT00153933 | Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 58 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT00084838 | Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT | completed | Phase 2 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 24, 2015 | clinicaltrials |
| NCT00575965 | Simvastatin in Waldenstrom's Macroglobulinemia | terminated | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 16, 2015 | clinicaltrials |
| NCT00148720 | Capecitabine in Women With Operable Breast Cancer | terminated | Phase 2 | 80 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 11, 2015 | clinicaltrials |
| NCT01586182 | Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 4, 2015 | clinicaltrials |
| NCT01222572 | Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 1 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00130689 | Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer | completed | Phase 2 | 43 | Dana-Farber Cancer InstituteOTHER | 1 | May 14, 2015 | clinicaltrials |
| NCT00476476 | Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar | completed | Phase 2 | 41 | Dana-Farber Cancer InstituteOTHER | 1 | May 7, 2015 | clinicaltrials |
| NCT00194493 | Computerized Assessment for Patients With Cancer(ESRA-C) | completed | Phase 3 | 1,058 | Dana-Farber Cancer InstituteOTHER | 1 | May 4, 2015 | clinicaltrials |
| NCT00692653 | Personal Patient Profile Prostate (P4) Randomized, Multisite Trial(P4) | completed | N/A | 498 | Dana-Farber Cancer InstituteOTHER | 1 | May 4, 2015 | clinicaltrials |
| NCT00585637 | Vitamin D for Chemoprevention | completed | Phase 1 | 328 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 1, 2015 | clinicaltrials |
| NCT01805089 | Melatonin Versus Placebo in Breast Cancer | completed | Early Phase 1 | 95 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 23, 2015 | clinicaltrials |
| NCT01853345 | iCAT for Recurrent/Refractory/HR Solid Tumors | completed | — | 101 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 10, 2015 | clinicaltrials |
| NCT00588107 | A Web Site and Print Materials Intervention for Smoking Intervention for Childhood and Young Adult Cancer Survivors(PFH2) | completed | N/A | 374 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 31, 2014 | clinicaltrials |
| NCT00894855 | Skin Cancer Screening and Education at Beaches(SHADE) | completed | N/A | 634 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 31, 2014 | clinicaltrials |
| NCT01761747 | Ponatinib for Squamous Cell Lung and Head and Neck Cancers | terminated | Phase 2 / Phase 3 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00165490 | Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer | completed | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 10, 2014 | clinicaltrials |
| NCT00098865 | Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma | completed | Phase 2 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 7, 2014 | clinicaltrials |
| NCT00357500 | Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer | completed | Phase 2 | 101 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 1, 2014 | clinicaltrials |
| NCT00409292 | RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 11, 2014 | clinicaltrials |
| NCT00215514 | Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma | completed | Early Phase 1 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 29, 2014 | clinicaltrials |
| NCT01491633 | Dasatinib in Advanced Squamous Cell Lung Cancer | terminated | Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 15, 2014 | clinicaltrials |
| NCT00165308 | Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors | completed | N/A | 29 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 9, 2014 | clinicaltrials |
| NCT00418093 | Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma | terminated | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 19, 2014 | clinicaltrials |
| NCT00674011 | Hypertension in Breast Cancer Patients Receiving Bevacizumab | terminated | — | 10 | Dana-Farber Cancer InstituteOTHER | 1 | May 6, 2014 | clinicaltrials |
| NCT00130702 | Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia | completed | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | May 1, 2014 | clinicaltrials |
| NCT00942682 | Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | completed | Phase 1 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 29, 2014 | clinicaltrials |
| NCT01961128 | RPFNA Assessment of Exercise Effect in Breast Cancer | completed | N/A | 2 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 29, 2014 | clinicaltrials |
| NCT00119730 | Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 24, 2014 | clinicaltrials |
| NCT00165516 | Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate | completed | Phase 2 | 85 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 27, 2014 | clinicaltrials |
| NCT00165555 | Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma | completed | Phase 1 | 70 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 27, 2014 | clinicaltrials |
| NCT00379587 | Rituximab for Prevention of Chronic GVHD | completed | Phase 1 / Phase 2 | 65 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 19, 2014 | clinicaltrials |
| NCT00095875 | Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial) | completed | Phase 3 | 145 | Dana-Farber Cancer InstituteOTHER | 2 | Nov 19, 2013 | clinicaltrials |
| NCT00496665 | ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer | completed | Phase 1 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 18, 2013 | clinicaltrials |
| NCT00483262 | Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 63 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 11, 2013 | clinicaltrials |
| NCT00973440 | Computer-Based Comprehensive Geriatric Assessment in Oncology for Individuals 70 or Older With Gastrointestinal Malignancies | completed | — | 59 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 22, 2013 | clinicaltrials |
| NCT00369226 | Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 25, 2013 | clinicaltrials |
| NCT00005627 | Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 1 | — | Dana-Farber Cancer InstituteOTHER | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00020618 | Inhaled Morphine Compared With Morphine By Mouth in Treating Cancer Patients With Breakthrough Pain | completed | Phase 2 | — | Dana-Farber Cancer InstituteOTHER | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00021996 | Valdecoxib in Treating Chronic Pain in Cancer Patients | completed | N/A | — | Dana-Farber Cancer InstituteOTHER | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00058487 | Epirubicin and Thalidomide in Treating Patients With Liver Cancer | completed | Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 18, 2013 | clinicaltrials |
| NCT01402687 | SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT) | completed | — | 181 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00459043 | Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 3, 2013 | clinicaltrials |
| NCT01600807 | OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas | withdrawn | Phase 1 / Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 26, 2013 | clinicaltrials |
| NCT01834183 | Tivozanib + Gemcitabine in Metastatic RCC | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00126191 | Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma | terminated | Phase 2 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | May 23, 2013 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials